LXRX Lexicon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LXRX

Price (delayed)

$3.18

Market cap

$602.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.63

Enterprise value

$631.1M

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes ...

Highlights
Lexicon Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 13% from the previous quarter
LXRX's debt has surged by 131% year-on-year
LXRX's revenue has plunged by 59% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lexpharma.com
Peers: REGN RARE ESPR BMRN

Key stats

What are the main financial stats of LXRX
Market
Shares outstanding
189.56M
Market cap
$602.81M
Enterprise value
$631.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.82
Price to sales (P/S)
4,770.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,008.77
Earnings
Revenue
$126,000
EBIT
-$105.91M
EBITDA
-$105.48M
Free cash flow
-$98.54M
Per share
EPS
-$0.63
Free cash flow per share
-$0.52
Book value per share
$0.47
Revenue per share
$0
TBVPS
$0.63
Balance sheet
Total assets
$162.72M
Total liabilities
$74.67M
Debt
$54.3M
Equity
$88.05M
Working capital
$89.18M
Liquidity
Debt to equity
0.62
Current ratio
5.38
Quick ratio
5.21
Net debt/EBITDA
-0.27
Margins
EBITDA margin
-83,715.1%
Gross margin
100%
Net margin
-87,620.6%
Operating margin
-86,128.6%
Efficiency
Return on assets
-66.8%
Return on equity
-105.1%
Return on invested capital
-94.8%
Return on capital employed
-74.4%
Return on sales
-84,056.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LXRX stock price

How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
9.66%
1 week
5.65%
1 month
31.95%
1 year
89.29%
YTD
66.49%
QTD
30.86%

Financial performance

How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$126,000
Gross profit
$126,000
Operating income
-$108.52M
Net income
-$110.4M
Gross margin
100%
Net margin
-87,620.6%
LXRX's net margin has dropped by 199% year-on-year and by 19% since the previous quarter
LXRX's operating margin has dropped by 196% year-on-year and by 19% since the previous quarter
LXRX's revenue has plunged by 59% YoY and by 9% from the previous quarter
The company's gross profit has shrunk by 59% YoY and by 9% QoQ

Growth

What is Lexicon Pharmaceuticals's growth rate over time

Valuation

What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.82
P/S
4,770.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,008.77
The P/B is 79% higher than the last 4 quarters average of 3.8
Lexicon Pharmaceuticals's equity has decreased by 25% QoQ and by 5% YoY
LXRX's price to sales (P/S) is 61% more than its last 4 quarters average of 2958.5
LXRX's revenue has plunged by 59% YoY and by 9% from the previous quarter

Efficiency

How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has shrunk by 189% YoY and by 18% QoQ
LXRX's ROIC has soared by 81% YoY and by 15% from the previous quarter
The company's return on equity fell by 40% YoY and by 9% QoQ
LXRX's ROA is down by 14% YoY and by 3.9% QoQ

Dividends

What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXRX.

Financial health

How did Lexicon Pharmaceuticals financials performed over time
The total assets is 118% greater than the total liabilities
LXRX's total liabilities has surged by 72% year-on-year but it is down by 3.2% since the previous quarter
The total assets has grown by 19% year-on-year but it has declined by 16% since the previous quarter
LXRX's debt is 38% smaller than its equity
Lexicon Pharmaceuticals's debt to equity has surged by 148% YoY and by 35% QoQ
LXRX's debt has surged by 131% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.